Back to top
more

OpGen (OPGN)

(Delayed Data from OTC)

$1.65 USD

1.65
1,440

-0.10 (-5.71%)

Updated Nov 6, 2024 03:43 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 45% (137 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Avantor (AVTR) Catches Eye: Stock Jumps 7.8%

by Zacks Equity Research

Avantor (AVTR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Teladoc's (TDOC) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Teladoc's (TDOC) first-quarter earnings gain from higher revenues, partly offset by a rise in expenses.

Teladoc to Buy InTouch Health, Expand Reach in Virtual Care

by Zacks Equity Research

Teladoc (TDOC) to acquire InTouch Health and provide virtual health solutions ranging from critical to everyday care.

Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo

by Zacks Equity Research

Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo

Sanghamitra Saha headshot

Adopt Rising P/E Technique With These 5 Top-Ranked Stocks

by Sanghamitra Saha

What bargain hunting? Stocks with a rising P/E can also be worth buying too.

OpGen, Inc. (OPGN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -28.46% and -28.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will OpGen, Inc. (OPGN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will OpGen, Inc. (OPGN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OpGen, Inc. (OPGN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -24.24% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will OpGen, Inc. (OPGN) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teladoc's Partnership to Form Pediatric Telehealth Platform

by Zacks Equity Research

Teladoc (TDOC) teams up with Cincinnati Children's Hospital Medical Center to launch consumer pediatric telehealth platform.

HealthEquity (HQY) Surges: Stock Moves 8.6% Higher

by Zacks Equity Research

HealthEquity (HQY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Teladoc Expands Services with Virtual Back Pain Treatment

by Zacks Equity Research

Teladoc's (TDOC) new addition of virtual back pain treatment will broaden its suite of products and services.

Sreyoshi Mukherjee headshot

3 Medical Services Stocks to Buy in 2019: HQY, AMEH & OPGN

by Sreyoshi Mukherjee

Here we discuss three profitable Medical Services stocks as the industry booms.

OpGen, Inc. (OPGN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 3.64% and -1.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Acadia Healthcare to Benefit from Growing Behavioral Issues

by Zacks Equity Research

Acadia Healthcare (ACHC) is well placed to serve patients with increasing incidence of behavioral and mental health illness.

    HCA Healthcare Up 11% Since Q2, Will the Rally Continue?

    by Zacks Equity Research

    HCA Healthcare's (HCA) shares rallied led by strong second-quarter results.

      Teladoc (TDOC) Up 26% in 22 Days, Will Upside Continue?

      by Zacks Equity Research

      Teladoc (TDOC) shares gain on strong operating performance in second quarter.

        Teladoc (TDOC) Hits 52-Week High, Will the Rally Continue?

        by Zacks Equity Research

        Strong second-quarter earnings performance and favorable guidance pulled up the stock of Teladoc (TDOC).

          Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS

          by Zacks Equity Research

          Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS

            Sanghamitra Saha headshot

            5 Top-Ranked Stocks to Benefit From Rising P/E Investing

            by Sanghamitra Saha

            Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

              HealthEquity (HQY) Looks Good: Stock Adds 11.5% in Session

              by Zacks Equity Research

              HealthEquity (HQY) was a big mover last session, as the company saw its shares rise more than 11% on the day amid huge volumes.

                Why Civitas Solutions (CIVI) Could Be Positioned for a Slump

                by Zacks Equity Research

                It seems to be a wise decision for investors to drop Civitas Solutions (CIVI) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.

                  What Falling Estimates & Price Mean for INC Research (INCR)

                  by Zacks Equity Research

                  INC Research (INCR) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.